Metals ions and neurodegeneration.
Neurodegenerative disorders include a variety of pathological conditions, which share similar critical metabolic processes such as protein aggregation and oxidative stress, both of which are associated with the involvement of metal ions. In this review Alzheimer's disease and Parkinson's disease are mainly discussed, with the aim of identifying common trends underlying these neurological conditions. Chelation therapy could be a valuable therapeutic approach, since metals are considered to be a pharmacological target for the rationale design of new therapeutic agents directed towards the treatment of neurodegeneration.
Molina-Holgado
Francisco
F
Wolfson Centre for Age Related Diseases, King's College, London, UK.
Hider
Robert C
RC
Gaeta
Alessandra
A
Williams
Robert
R
Francis
Paul
P
D016229:Amyloid beta-Peptides / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007477:Ions / Q000737:chemistry / Q000378:metabolism; D007502:Iron Chelating Agents / Q000378:metabolism / Q000627:therapeutic use; D008670:Metals / Q000737:chemistry / Q000378:metabolism; D015394:Molecular Structure; D019636:Neurodegenerative Diseases / Q000378:metabolism* / Q000628:therapy; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D011328:Prions / Q000235:genetics / Q000378:metabolism; D051844:alpha-Synuclein / Q000235:genetics / Q000378:metabolism
D016229:Amyloid beta-Peptides; D007477:Ions; D007502:Iron Chelating Agents; D008670:Metals; D011328:Prions; D051844:alpha-Synuclein